HC Wainwright Reaffirms “Buy” Rating for OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 469.11% from the company’s previous close. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Stock Performance

Shares of NASDAQ OKYO opened at $1.23 on Thursday. The business has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.24. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.